TYROBP

Across TCGA pan-cancer cohorts, TYROBP Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TYROBP data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher TYROBP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TYROBP expression acts as an unfavorable survival marker.

ESCA, MESO, and UCEC are the cancer types where TYROBP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.108	0.703	<.001	36	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	OS	Median	All	0.252	0.729	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TYROBP–ESCA (OS)

Open the ESCA breakdown →